Category: Expand Collaboration

  • Exelixis Expands its Collaboration with Invenra to Develop Novel Biologics in Oncology

    Shots: Invenra to receive $15.0M up front along with additional fees and funding to elect up to 20 additional targets in oncology & is eligible for development, regulatory, and commercial milestones along with royalties on net sales of any approved products Exelixis will own all Ab sequences discovered from the collaboration for uses in oncology […]